Bendamustine in the treatment of non-Hodgkin’s lymphomas

Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center Houston, TX, USA
OncoTargets and Therapy (Impact Factor: 2.31). 02/2009; 2:269-79. DOI: 10.2147/OTT.S4873
Source: PubMed

ABSTRACT To review available data using bendamustine alone and in combination with other chemotherapeutic agents in treatment of patients with non-Hodgkin's lymphomas.
Internet database searches and literature review.
Bendamustine was approved in March 2008 by the United States Food and Drug Administration for the treatment of patients with chronic lymphocytic leukemia. Many trials have been performed over the last decade using bendamustine not only as monotherapy, but also in combination with other agents including rituximab, vincristine, mitoxantrone, fludarabine, and other agents as therapy for patients with relapsed non-Hodgkin's lymphomas, and recently was approved for use in therapy of patients with relapsed indolent lymphomas considered refractory to rituximab therapy. As monotherapy, bendamustine induces good responses with only minor side effects. In combination with other agents, efficacy improves, especially when given in combination with rituximab. The drug has also been studied in combination with rituximab as initial therapy for indolent lymphomas, and has excellent activity with less toxicity than R-CHOP (rituximab - cyclophosphamide, hydroxydaunorubicin [Adriamycin], Oncovin [vincristine], and prednisone/prednisolone).
Overall, bendamustine has demonstrated promising results as therapy for non-Hodgkin's lymphomas and should be included in the armamentarium of agents used to treat relapsed indolent non-Hodgkin's lymphomas and may prove valuable as initial therapy for these diseases. Further studies are being conducted to demonstrate the efficacy of this drug in combination with other agents.

9 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ability of three cytostatic alkylating agents to form cross-links with DNA has been investigated by renaturation experiments. Two of them, IMET 3943 and 3106, are effective in renaturing DNA in vitro after treatment in Tris buffer solution. The relative high bifunctional alkylation tendency found for IMET 3106 can be attributed to its cancerostatic active degradation product .
    Biochimica et Biophysica Acta 01/1973; 287(3):386-9. DOI:10.1016/0005-2787(72)90282-1 · 4.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melphalan and BCNU, suggesting only incomplete cross-resistance. Furthermore lower levels of resistance were also observed in all breast cancer cell lines when bendamustine hydrochloride was compared with cisplatin. Bendamustine hydrochloride also presents good activity in cell line MCF 7 AD, which is approximately 80-fold resistant to doxorubicin compared with MCF 7. Basic glutathione levels and activity of glutathione-S-transferase showed no correlation to the IC50 values for bendamustine hydrochloride in the cell lines. When given at equitoxic concentrations, bendamustine hydrochloride consistently induced more DNA double-strand breaks than melphalan, cyclophosphamide or BCNU. In addition, removal of DNA double-strand breaks induced by bendamustine hydrochloride was relatively slow with the majority of DNA double-strand breaks still being detectable after 24 h. These findings indicate differences in the interaction between bendamustine hydrochloride and DNA, and may explain the lack of complete cross-resistance between bendamustine hydrochloride and the other alkylating agents.
    Anti-Cancer Drugs 07/1996; 7(4):415-21. DOI:10.1097/00001813-199606000-00007 · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bendamustine is an alkylating agent which also shows properties of a purine analog. Because of its unique mechanism of action it shows activity in relapsed indolent lymphomas which are resistant to alkylating agents, purine analogs, and rituximab. Bendamustine has a favorable toxicity profile causing no alopecia and only a moderate hematotoxicity and gastrointestinal toxicity. Combinations of bendamustine with mitoxantrone and rituximab and with rituximab alone have been shown to be highly active in relapsed/refractory indolent lymphomas and mantle cell lymphomas achieving long lasting complete remissions. Because of only moderate toxicity these combinations can be applied safely in elderly patients who can be treated in an outpatient setting.
    Therapeutics and Clinical Risk Management 09/2008; 4(4):727-32. · 1.47 Impact Factor
Show more

Preview (2 Sources)

9 Reads
Available from